The Boston-based Institute for Clinical and Economic Review (ICER), an independent research organization that conducts health technology assessments to examine the clinical and economic value of prescription drugs, medical tests and other health care and health care delivery innovations, announced on November 13, 2019, that in 2020, they are considering selecting two or more non-drug topics for assessment. On their list for potential evaluations are topics ranging from lenses for cataracts to apps for managing anxiety and depression. These first evaluations will be an extension of ICER’s research on prescription drugs as they work to adapt their experience in decision modelling for pharmaceutical products to models for devices, diagnostics, digital health, procedures, apps, health programs and more.
ICER’s extension into non-drug assessments will have substantial implications for device, diagnostic and digital therapeutic innovators, as their new paradigm will allow for comparison of not only drugs against each other (or the natural history of disease) but also a comparison of products from different spaces within the life sciences industry. For example, also making their shortlist is a potential comparison of devices for atrial fibrillation compared to the oral anticoagulant, dabigatran.
In addition to this broader evaluation scope, ICER recently undertook their bi-annual value framework update, with the final details released on January 31, 2020. The changes made in this framework have significant implications, both positive and negative, for all health technology organizations facing the prospect of an evaluation. Understanding the updated framework and ways to work within ICER’s established processes is essential for success in ensuring that appropriate pre-evaluation research is undertaken, enabling the sponsor to provide cohesive and compelling input during the evaluation process.
The experts from Boston Healthcare Associates regularly leverage their expertise in health economics and outcomes research to assist clients with health economic modelling and ICER planning. In this webinar, participants will learn about the updated 2020 value framework, how ICER’s new evaluations may impact your technologies, and how to best prepare for and participate in the evaluation process.
Jordan Hinahara, Senior Manager, Boston Healthcare Associates
Jordan Hinahara is a member of the health economics team with over five years of market access experience and an academic background in stochastic modeling and health decision sciences, including past positions as a researcher and instructor in health services research and cost-effectiveness modelling during her graduate studies at the University of Minnesota. Her experience in market access spans across both the public and private sectors in the US, Asian, European and Latin American markets, with a focus on health policy and health economic modelling. Jordan has supported various economic evaluation and technology assessment projects across the device, diagnostic and pharmaceutical space, with specific expertise in the evaluation of screening programs. She holds a Bachelor’s in Health Policy from Brandeis University.
Thomas F. Goss, Senior Vice President, Boston Healthcare Associates
Thomas Goss has more than 20 years of experience managing and directing healthcare research, including examination of the impact of public and private payor policy on patient access, assessment of health-related quality-of-life, patient preference and patient satisfaction associated with healthcare interventions, and evaluation of health economic outcomes associated with healthcare innovations. His work in health economic assessment includes the development of health economic evaluations (cost-effectiveness and budget impact analysis) for multiple markets including the US, EU-5, Japan and other markets He also directs disease management program evaluations using patient outcomes data. He has published extensively in these areas and has more than 50 peer-reviewed publications and over 90 peer-reviewed abstracts and invited publications.
Prior to joining Boston Healthcare Associates, Dr. Goss was vice president and director of consulting services at Covance Market Access Services, where he had a 15-year career with increasing levels of responsibility in the areas of client management and executive management.
Dr. Goss received a PharmD from the State University of New York at Buffalo, and a Bachelor of Science from the Albany College of Pharmacy. He completed graduate coursework in Epidemiology and a postdoctoral fellowship in Pharmacoepidemiology and Outcomes Research at the State University of New York at Buffalo. Dr. Goss has authored chapters in the American College of Clinical Pharmacy Textbook Pharmacoeconomics and Outcomes: Applications for Patient Care and has participated in the ACCP Outcomes and Economics Practice Research Network and has held memberships and presented at the International Society of Pharmacoeconomics and Outcomes Research and the Academy of Managed Care Pharmacy. Dr. Goss is currently an appointee to the US Center for Medicare & Medicaid Services (CMS) Medicare Evidence Development & Coverage Advisory Committee (MEDCAC).
Who Should Attend?
This webinar will appeal to senior-level professionals including managers/directors working within:
- Clinical Affairs
- Payer Policy
- Managed Care
- Commercial Affairs
- Market Access
- Market Pricing
- Market Engagement
- Health Economics
- Government Affairs
- Patient Marketing
- Patient Advocacy
What You Will Learn
Attendees will learn:
- How biopharma and medtech innovators can optimize engagement with ICER under the updated 2020 value framework.
- How ICER’s new evaluation may impact your technologies
- How to best prepare for and participate in the evaluation process
Boston Healthcare is a global strategy consulting firm that provides market access and value optimization strategies to healthcare technology and service innovators. We help clients unlock the value of medical devices, diagnostics, biopharmaceuticals, and informatics that have the potential to transform patient care and significantly improve health outcomes.